PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
20052460-8	2010	Our study indicated that scutellarin exerts its anti-hypertrophic activity via suppressing the Ca(2+)-mediated calcineurin and CaMKII pathways, which supports the observation that clinical application of scutellarin is beneficial for cardiovascular disease patients.	scutellarin	204-215	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	127-133	
20052460-0	2010	Scutellarin exerts its anti-hypertrophic effects via suppressing the Ca2+-mediated calcineurin and CaMKII signaling pathways.	scutellarin	0-11	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	99-105	
20052460-7	2010	The expression of calcium downstream effectors calcineurin and phosphorylated calmodulin kinase II (CaMKII) were significantly suppressed by scutellarin.	scutellarin	141-152	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	78-98	
20052460-7	2010	The expression of calcium downstream effectors calcineurin and phosphorylated calmodulin kinase II (CaMKII) were significantly suppressed by scutellarin.	scutellarin	141-152	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	100-106	
20052460-8	2010	Our study indicated that scutellarin exerts its anti-hypertrophic activity via suppressing the Ca(2+)-mediated calcineurin and CaMKII pathways, which supports the observation that clinical application of scutellarin is beneficial for cardiovascular disease patients.	scutellarin	25-36	calcium/calmodulin dependent protein kinase II gamma	Homo sapiens	127-133